Evidence map›Paper›PMID 36496490›Full record

Observational studyAnnals of surgical oncology2023

Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model.

Claudia J C Meurs, Joost van Rosmalen, Marian B E Menke-Pluijmers, Sabine Siesling, Pieter J Westenend

Open access · hybridFull text readObservational Study
In one paragraph

Observational study in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Claudia J C MeursDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.ORCID http://orcid.org/0000-0002-8643-3717
Joost van RosmalenDepartment of Biostatistics, Erasmus MC, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9187-244X
Marian B E Menke-PluijmersDepartment of Surgery, Albert Schweitzer Hospital, Dordrecht, The Netherlands.ORCID http://orcid.org/0000-0003-3301-4962
Sabine SieslingDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.ORCID http://orcid.org/0000-0002-0273-824X
Pieter J WestenendLaboratory of Pathology Dordrecht, Dordrecht, The Netherlands. pwestenend@paldordrecht.nl.ORCID http://orcid.org/0000-0002-5509-920X
Albert Schweitzer Ziekenhuis · NLDordrecht Hospital · ZAErasmus MC · NLNetherlands Comprehensive Cancer Organisation · NLUniversity of Twente · NL

Funding

KWF Kankerbestrijding SLP2015-7769
6 · The paper itself

Abstract

purposeIn patients with a biopsy-proven ductal carcinoma in situ (DCIS), axillary staging is frequently performed, but in hindsight often turns out to be superfluous. The aim of this observational study was to develop a prediction model for risk of lymph node metastasis in patients with a biopsy-proven DCIS.

methodsData were received from the Dutch Pathology Databank and the Netherlands Cancer Registry. The population-based cohort consisted of all biopsy-proven DCIS patients diagnosed in the Netherlands in 2011 and 2012. The prediction model was evaluated with the area under the curve (AUC) of the receiver operating characteristic, and a calibration plot and a decision curve analysis and was validated in a Dutch cohort of patients diagnosed in the period 2016-2019.

resultsOf 2892 biopsy-proven DCIS patients, 127 had metastasis (4.4%). Risk factors were younger age (OR = 0.97, 95% CI 0.95-0.99), DCIS not detected by screening (OR = 1.55, 95% CI 1.01-2.38), suspected invasive component at biopsy (OR = 1.86, 95% CI 1.01-3.41), palpable tumour (OR = 2.06, 95% CI 1.34-3.18), BI-RADS score 5 (OR = 2.41, 95% CI 1.53-3.78), intermediate-grade DCIS (OR = 3.01, 95% CI 1.27-7.15) and high-grade DCIS (OR = 3.20, 95% CI 1.36-7.54). For 24% (n = 708) of the patients, the predicted risk of lymph node metastasis was above 5%. Based on the decision curve analysis, the model had a net benefit for a predicted risk below 25%. The AUC was 0.745. Of the 2269 patients in the validation cohort, 53 (2.2%) had metastasis and the AUC was 0.741.

conclusionsThis DCIS-met model can support clinical decisions on axillary staging in patients with biopsy-proven DCIS.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingAxillaBiopsyBreastFemaleHumansLymphatic MetastasisRetrospective StudiesSentinel Lymph Node Biopsy

Identifiers

PMID36496490
PMCPMC10027636
OpenAlexW4311114307

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read103
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.